帕罗西汀治疗帕金森病伴发抑郁的临床效果

Abstract
Figure/Table
References (19)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract [Abstract]Objective To investigate the clinical effect of Paroxetine in the treatment of Parkinson′s disease with depression.Mehods Sixty patients with Parkinson′s disease accompanied by depression who were admitted to our hospital from January 2018 to January 2019 were selected as the research subjects，they were divided into observation group and control group according to the random number allocation principle，with 30 cases in each group.The control group was given routine treatment，and the observation group was treated with Paroxetine Tablets on the basis of the control group for 8 weeks.The unified Parkinson′s disease rating scale（UPDRS）and Hamilton depression scale（HAMD）scores were compared before and after treatment.Results The UPDRS score of the observation group was lower than that of the control group 8 weeks after treatment，the difference was statistically significant（P＜0.05）.The HAMD score of the observation group was lower than that of the control group at 4 and 8 weeks after treatment，the differences were statistically significant（P＜0.05）.Conclusion The application of Paroxetine in the treatment of Parkinson′s disease with depression can alleviate the symptoms and depression of patients，which is worthy of clinical application.

Key words： Parkinson′s disease Anti-depressant Paroxetine Depressive disorder

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I4/66

[1]	张英，王才善，盛余敬，等.帕金森病患者经颅超声中缝核回声变化与抑郁的相关性[J].中华实用诊断与治疗杂志，2019，33（7）：697-699.
[2]	张星星，周晨，段宏为，等.认知行为疗法减轻帕金森病患者抑郁或焦虑的Meta分析[J].中国全科医学，2019，22（17）：2084-2090.
[3]	Santos García D，de Deus Fonticoba T，Suárez Castro E，et al.Non-motor symptoms burden，mood，and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson′s disease patients：results from the COPPADIS study cohort[J].Parkinsonism Relat Disord，2019，66：151-157.
[4]	李锐，李远辉，丁巧方，等.帕金森病合并焦虑抑郁的患病率及危险因素[J].河南医学研究，2019，28（1）：31-33.
[5]	曾培灿，孙光裕，曾宪杰，等.盐酸帕罗西汀片对帕金森患者伴发抑郁症状的临床疗效[J].现代诊断与治疗，2015，26（14）：3183-3184.
[6]	中华医学会神经病学分会帕金森病及运动障碍学组.中国帕金森病治疗指南（第三版）[J].中华神经科杂志，2014，47（6）：428-433.
[7]	张淑琴，吴丹，欧阳存，等.UPDRS评分对帕金森病临床疗效的影响因素分析[J].国际老年医学杂志，2019，40（3）：137-139，146.
[9]	张丹丹，张宇新，张乘云，等.G-CSF 对帕金森病小鼠运动能力和黑质纹状体神经元的影响[J].神经解剖学杂志，2019，35（1）：1-7.
[11]	赖穗翩，陈钜涛，黎冠东.司来吉兰与普拉克索分别辅助多巴丝肼片治疗中晚期帕金森病的效果对比[J].中国当代医药，2019，26（4）：80-82.
[8]	Lin CH，Park C，McIntyre RS.Early improvement in HAMD-17 and HAMD-7 scores predict response and remission in depressed patients treated with fluoxetine or electroconvulsive therapy[J].J Affect Disord，2019，253：154-161.
[10]	Huang L，Ren Y，Zeng Z，et al.Comparative study of striatum GABA concentrations and magnetic resonance spectroscopic imaging in Parkinson′s disease monkeys[J].BMC Neurosci，2019，20（1）：42.
[12]	Barbosa ENBE，Charchat-Fichman H.Systematic review of neuropsychological instruments used in subthalamic nucleus deep brain stimulation in Parkinson′s disease patients[J].Dement Neuropsychol，2019，13（2）：162-171.
[13]	刘丹.普拉克索治疗老年帕金森病伴发抑郁症的治疗效果观察[J].中国医药指南，2017，15（28）：163-164.
[14]	Aboulghasemi N，Hadipour Jahromy M，Ghasemi A.Antidyskinetic efficacy of 5-HT3 receptor antagonist in the hemi-parkinsonian rat model[J].IBRO Rep，2018，6：40-44.
[15]	孙政，杜小静，马建军，等.抑郁对不同运动亚型帕金森病患者生活质量的影响[J].中华老年心脑血管病杂志，2019，21（2）：129-132.
[16]	连腾宏，左丽君，郭鹏，等.帕金森病伴发抑郁的神经生化机制及白质纤维的变化[J].中国神经免疫学和神经病学杂志，2018，25（5）：311-315.
[17]	Carboni L，McCarthy DJ，Delafont B，et al.Biomarkers for response in major depression：comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies[J].Transl Psychiatry，2019，9（1）：182.
[18]	Purgato M，Papola D，Gastaldon C，et al.Paroxetine versus other anti-depressive agents for depression[J].Cochrane Database Syst Rev，2014，（4）：CD006531.
[19]	郑丽芬，林萍，张旭，等.帕罗西汀片联合普拉克索片治疗帕金森病伴抑郁的临床研究[J].中国临床药理学杂志，2018，34（15）：1819-1821.